Sound Shore Management Inc. CT Cuts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Sound Shore Management Inc. CT decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 970,225 shares of the medical equipment provider’s stock after selling 46,739 shares during the quarter. Hologic accounts for 2.3% of Sound Shore Management Inc. CT’s portfolio, making the stock its 24th largest position. Sound Shore Management Inc. CT owned about 0.43% of Hologic worth $69,944,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the company. State Street Corp boosted its holdings in Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares during the last quarter. FMR LLC boosted its holdings in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after purchasing an additional 24,358 shares during the last quarter. Boston Partners boosted its holdings in Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after purchasing an additional 18,774 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HOLX. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Royal Bank of Canada decreased their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Citigroup decreased their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $84.62.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $61.47 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a market cap of $13.79 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. The firm’s fifty day moving average is $66.06 and its two-hundred day moving average is $73.94. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.